Evidence map›Paper›PMID 31013363›Full record

Trial reportHepatology (Baltimore, Md.)2019

MRI Assessment of Treatment Response in HIV-associated NAFLD: A Randomized Trial of a Stearoyl-Coenzyme-A-Desaturase-1 Inhibitor (ARRIVE Trial).

Veeral H Ajmera, Edward Cachay, Christian Ramers, Irine Vodkin, Shirin Bassirian, Seema Singh, Neeraj Mangla, Richele Bettencourt, Jeannette L Aldous, Daniel Park and 9 more

Registry-linked trialOpen access · greenAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Hepatology (Baltimore, Md.), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05184283 (Longitudinal Assessment of Muscle Health in Patients Undergoing Liver Transplantation), which is not on this map. Cited by 28 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed, 1 pooled it
4.3field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05184283 terminatednot on this mapstarted 2022, after this paper: background citation

Longitudinal Assessment of Muscle Health in Patients Undergoing Liver Transplantation (LT) for Hepatocellular Carcinoma (HCC)

TypeobservationalSponsorColumbia UniversityRan2022 to 2023Enrolled11ConditionsNAFLD, Hepatocellular Carcinoma, Liver Diseases, Liver Cancer
3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 1 synthesis or guideline pooled it, 41 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Review
  4. Liver disease in people living with HIV infection: a changing landscape.Nature reviews. Gastroenterology & hepatology · 2026
    Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Fatty Liver Disease: Enter the Metabolic Era.Current HIV/AIDS reports · 2023
    Review
  12. Review
  13. Review
  14. Article
  15. Article
  16. Review
  17. Treatment Candidacy for Pharmacologic Therapies for NASH.Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2022
    Review
  18. Expert Panel Review on Nonalcoholic Fatty Liver Disease in Persons With Human Immunodeficiency Virus.Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2022
    Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 5 institutions in 2 countries.

Veeral H AjmeraNAFLD Research Center, University of California San Diego Health, La Jolla, CA.ORCID 0000-0001-5626-0942
Edward CachayDivision of Infectious Diseases, Owen Clinic, University of California San Diego, San Diego, CA.
Christian RamersFamily Health Center, San Diego, CA.
Irine VodkinDivision of Gastroenterology, Department of Medicine, University of California San Diego Health, La Jolla, CA.
Shirin BassirianNAFLD Research Center, University of California San Diego Health, La Jolla, CA.
Seema SinghNAFLD Research Center, University of California San Diego Health, La Jolla, CA.
Neeraj ManglaNAFLD Research Center, University of California San Diego Health, La Jolla, CA.
Richele BettencourtNAFLD Research Center, University of California San Diego Health, La Jolla, CA.
Jeannette L AldousSan Ysidro Health, San Diego, CA.
Daniel ParkSan Ysidro Health, San Diego, CA.
Daniel LeeDivision of Infectious Diseases, Owen Clinic, University of California San Diego, San Diego, CA.ORCID 0000-0003-2959-890X
Jennifer BlanchardDivision of Infectious Diseases, Owen Clinic, University of California San Diego, San Diego, CA.
Adrija MamidipalliLiver Imaging Group, University of California San Diego, La Jolla, CA.
Andrew BoehringerLiver Imaging Group, University of California San Diego, La Jolla, CA.
Saima AslamDivision of Infectious Diseases and Global Public Health, University of California San Diego, San Diego, CA.
Olof Dahlqvist LeinhardAMRA Medical AB, Linköping, Sweden.
Lisa RichardsNAFLD Research Center, University of California San Diego Health, La Jolla, CA.
Claude SirlinLiver Imaging Group, University of California San Diego, La Jolla, CA.
Rohit LoombaNAFLD Research Center, University of California San Diego Health, La Jolla, CA.
University of California San Diego · USSan Ysidro Health · USHealth Center · USLinköping University · SEUniversity of California System · US

Funding

QUS Technology for Diagnosis and Grading of Hepatic Steatosis in NAFLDR01DK106419 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI LOOMBA, ROHIT, SIRLIN, CLAUDE B · 2015 to 2019
$3.4M
A Novel Multimodal Approach to Characterize NAFLD Severity and PrognosisK23DK119460 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI AJMERA, VEERAL HARESH · 2019 to 2023
$1.1M
American Association for the Study of Liver Diseases' Foundation Clinical and Translational Research AwardAtlantic Philanthropies, Inc.GALMEDNIDDK NIH HHS K23 DK119460NIDDK NIH HHS R01 DK106419the John A. Hartford Foundation
6 · The paper itself

Abstract

Aramchol, an oral stearoyl-coenzyme-A-desaturase-1 inhibitor, has been shown to reduce hepatic fat content in patients with primary nonalcoholic fatty liver disease (NAFLD); however, its effect in patients with human immunodeficiency virus (HIV)-associated NAFLD is unknown. The aramchol for HIV-associated NAFLD and lipodystrophy (ARRIVE) trial was a double-blind, randomized, investigator-initiated, placebo-controlled trial to test the efficacy of 12 weeks of treatment with aramchol versus placebo in HIV-associated NAFLD. Fifty patients with HIV-associated NAFLD, defined by magnetic resonance imaging (MRI)-proton density fat fraction (PDFF) ≥5%, were randomized to receive either aramchol 600 mg daily (n = 25) or placebo (n = 25) for 12 weeks. The primary endpoint was a change in hepatic fat as measured by MRI-PDFF in colocalized regions of interest. Secondary endpoints included changes in liver stiffness using magnetic resonance elastography (MRE) and vibration-controlled transient elastography (VCTE), and exploratory endpoints included changes in total-body fat and muscle depots on dual-energy X-ray absorptiometry (DXA), whole-body MRI, and cardiac MRI. The mean (± standard deviation) of age and body mass index were 48.2 ± 10.3 years and 30.7 ± 4.6 kg/m

Indexed as

Elasticity Imaging TechniquesMagnetic Resonance ImagingAdultCholic AcidsDouble-Blind MethodFemaleHIV InfectionsHumansMaleMiddle AgedNon-alcoholic Fatty Liver DiseasearamcholCholic Acids

Identifiers

PMID31013363
PMCPMC7164416
OpenAlexW2940528970

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.